一、市场: ●12月20日收盘：美股收高纳指涨逾300点 AI板块重拾升势 北京时间12月20日凌晨，美股周五收高，科技股领涨，纳指涨超300点。道指、纳指、标普500指数均收涨，本周三大股指涨跌不一。软件巨头甲骨文因 TikTok美国业务交易股价大涨，此前曾因债务和AI支出问题股价承压。英伟达收高，美光科技延续涨势。不过，市场或因"四重巫师日"出现剧烈波动，本周 五有超7.1万亿美元名义价值期权到期。此外，耐克因大中华区营收下滑及关税压力，股价收跌10.55%。有策略师认为AI相关企业发债潮或影响市场至2026 年，但企业有融资能力。 ●12月20日美股成交额前20：FTC批准英伟达投资英特尔 周五美股成交额前20的股票中，英伟达成交额居首，收高3.93%，成交580.42亿美元，FTC批准其对英特尔投资50亿美元，该交易或影响竞争格局。券商伯 恩斯坦称英伟达估值具吸引力，给予"跑赢大盘"评级。博通收高3.18%，特鲁斯特证券上调其目标价。特斯拉收跌，美最高法院恢复马斯克薪酬方案。谷歌 A类股收高，与派拓网络拓展合作。此外，美光、甲骨文、AMD等股票也有不同表现，如美光创历史新高，AMD苏姿丰访华交流。 ● ...

Core Viewpoint - The company intends to acquire Amicus Therapeutics for approximately $4.8 billion to expand its presence in the rare metabolic disease sector [1][3]. Group 1: Acquisition Details - The acquisition price is set at $14.50 per share, representing a 33.1% premium over Amicus's latest closing price [1][3]. - Following the announcement, Amicus's stock surged by 30%, while the acquiring company's stock rose nearly 5% in pre-market trading [1][3]. - The deal will enhance the company's product portfolio by adding several approved treatments for genetic diseases, including Galafold for Fabry disease and a combination therapy for Pompe disease [1][3]. Group 2: Financial Aspects - The company plans to finance the acquisition through existing cash reserves and approximately $3.7 billion in non-convertible debt [1][3]. - As of September 30, the company's total cash and investments amount to about $2 billion [2][4]. - The acquisition is expected to close in the second quarter of 2026 and will immediately contribute to revenue growth [2][4]. - The company anticipates that the acquisition will enhance adjusted profits within the first 12 months post-transaction and significantly boost earnings starting in 2027 [5].